Anurag Singh

Table S6 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S6. Antibodies used for preclinical experiments

Table S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S4. Treatment-Emergent Adverse Events (≥3 patients) with PF-07799933 monotherapy and combination therapy

Figure S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Figure S1. Preclinical characterization of PF-07799933 and comparison to other RAF inhibitors.

Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S5. Preliminary mutation analysis

Figure S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Figure S3. Mouse plasma PK profiles for exarafenib and plixorafenib.

Table S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S2. X-ray crystallography data collection and refinement statistics

Table S3 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S3. Demographic and clinical characteristics of the patients

Figure S4 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Figure S4. Patient PK profiles for PF-07799933.

Table S1 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Table S1. Cell lines used for cell-based pERK assays in Figure 1A

Figure S2 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Figure S2. Crystal structures of BRAF kinase domain with PF-07799933 or encorafenib.

Figure S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Rona Yaeger, Meredith McKean, Rizwan Haq, J. Thaddeus Beck et autres

Figure S5. Efficacy for BRAF non-V600/Class II and Class III-mutant cancer patients.

Abstract 1870: Characterizing drug-induced transcriptional reprogramming in KRAS mutant lung cancer.

Wafa Malik, Anurag Singh, Laurent Sansregret, Aaron N. Hata

Abstract KRAS mutations define the largest genomic subset of non-small cell lung cancer (NSCLC). Recently, inhibitors that selectively target the KRASG12C mutation (G12Ci) have been developed, however, clinical responses are incomplete and short-lived due to intrinsic and adaptive drug resistance. Combination drug …

us, ch (code pays fourni par la source)